HeronaMide C
![]() |
- $220 - $956
- Product name: HeronaMide C
- CAS: 1257083-94-5
- MF: C29H39NO3
- MW: 449.62
- EINECS:
- MDL Number:MFCD20923561
- Synonyms:HeronaMide C;Azacycloeicosa-3,5,7,11,13,15,17-heptaen-2-one, 9,10-dihydroxy-7,15-dimethyl-20-(2E,4E)-2,4-octadien-1-yl-, (3E,5E,7E,9S,10R,11Z,13E,15E,17E,20R)-
5 prices
Selected condition:
Brand
- Cayman Chemical
- TRC
- Usbiological
Package
- 1mg
- 2.5mg
- 5mg
- ManufacturerCayman Chemical
- Product number23644
- Product descriptionHeronamide C ≥95%
- Packaging1mg
- Price$225
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number23644
- Product descriptionHeronamide C ≥95%
- Packaging5mg
- Price$956
- Updated2024-03-01
- Buy
- ManufacturerTRC
- Product numberH281188
- Product descriptionHeronamideC
- Packaging1mg
- Price$220
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberH281188
- Product descriptionHeronamideC
- Packaging2.5mg
- Price$440
- Updated2021-12-16
- Buy
- ManufacturerUsbiological
- Product numberH2040-01
- Product descriptionHeronamide C
- Packaging1mg
- Price$513
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Cayman Chemical | 23644 | Heronamide C ≥95% | 1mg | $225 | 2024-03-01 | Buy |
Cayman Chemical | 23644 | Heronamide C ≥95% | 5mg | $956 | 2024-03-01 | Buy |
TRC | H281188 | HeronamideC | 1mg | $220 | 2021-12-16 | Buy |
TRC | H281188 | HeronamideC | 2.5mg | $440 | 2021-12-16 | Buy |
Usbiological | H2040-01 | Heronamide C | 1mg | $513 | 2021-12-16 | Buy |
Properties
Boiling point :668.3±55.0 °C(Predicted)
Density :0.990±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMSO: soluble; Methanol: unstable
form :A solid
pka :13.17±0.70(Predicted)
Density :0.990±0.06 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMSO: soluble; Methanol: unstable
form :A solid
pka :13.17±0.70(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|